BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37183047)

  • 1. Association of dynamic contrast-enhanced MRI and
    Withey SJ; Owczarczyk K; Grzeda MT; Yip C; Deere H; Green M; Maisey N; Davies AR; Cook GJ; Goh V;
    Eur J Surg Oncol; 2023 Oct; 49(10):106934. PubMed ID: 37183047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diffusion-weighted MRI and
    Xu X; Sun ZY; Wu HW; Zhang CP; Hu B; Rong L; Chen HY; Xie HY; Wang YM; Lin HP; Bai YR; Ye Q; Ma XM
    Radiat Oncol; 2021 Jul; 16(1):132. PubMed ID: 34281566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting Response to Neoadjuvant Chemoradiotherapy in Esophageal Cancer with Textural Features Derived from Pretreatment
    Beukinga RJ; Hulshoff JB; van Dijk LV; Muijs CT; Burgerhof JGM; Kats-Ugurlu G; Slart RHJA; Slump CH; Mul VEM; Plukker JTM
    J Nucl Med; 2017 May; 58(5):723-729. PubMed ID: 27738011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer.
    Kazerouni AS; Peterson LM; Jenkins I; Novakova-Jiresova A; Linden HM; Gralow JR; Hockenbery DM; Mankoff DA; Porter PL; Partridge SC; Specht JM
    Breast Cancer Res; 2023 Nov; 25(1):138. PubMed ID: 37946201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrence.
    Findlay JM; Dickson E; Fiorani C; Bradley KM; Mukherjee S; Gillies RS; Maynard ND; Middleton MR
    Eur Radiol; 2019 Dec; 29(12):6717-6727. PubMed ID: 31278574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete pathological response (pCR) in gastroesophageal cancer: Correlation with metabolic response.
    Cabral F; Cruz A; Casaca R; Monteiro C; Ramos P; Pedro C; Brandão F; Fonseca R; Ratão P; Salgado L; Pinto I; Abecasis N
    Cancer Radiother; 2020 Dec; 24(8):834-841. PubMed ID: 33191120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18 F-FDG PET/MRI for restaging esophageal cancer after neoadjuvant chemoradiotherapy.
    Valkema MJ; de Lussanet de la Sablonière QG; Valkema R; Thomeer MGJ; Dwarkasing RS; Harteveld AA; Doukas M; Mostert B; van der Zijden CJ; van der Sluis PC; Lagarde SM; Wijnhoven BPL; Verburg FA; van Lanschot JJB
    Nucl Med Commun; 2024 Feb; 45(2):128-138. PubMed ID: 37982560
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Mi L; Zhao Y; Zhao X; Yin F; Yin X; Li N; Shi J; Han X; Duan X; Zhao M; Han G; Wang J
    Cancer Biother Radiopharm; 2021 Oct; 36(8):662-671. PubMed ID: 32783634
    [No Abstract]   [Full Text] [Related]  

  • 9. Preoperative Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients With Esophageal Cancer Using
    Borggreve AS; Goense L; van Rossum PSN; Heethuis SE; van Hillegersberg R; Lagendijk JJW; Lam MGEH; van Lier ALHMW; Mook S; Ruurda JP; van Vulpen M; Voncken FEM; Aleman BMP; Bartels-Rutten A; Ma J; Fang P; Musall BC; Lin SH; Meijer GJ
    Int J Radiat Oncol Biol Phys; 2020 Apr; 106(5):998-1009. PubMed ID: 31987972
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting Pathologic Response of Esophageal Cancer to Neoadjuvant Chemotherapy: The Implications of Metabolic Nodal Response for Personalized Therapy.
    Findlay JM; Bradley KM; Wang LM; Franklin JM; Teoh EJ; Gleeson FV; Maynard ND; Gillies RS; Middleton MR
    J Nucl Med; 2017 Feb; 58(2):266-275. PubMed ID: 27635027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pilot study of serial FLT and FDG-PET/CT imaging to monitor response to neoadjuvant chemoradiotherapy of esophageal adenocarcinoma: correlation with histopathologic response.
    Gerbaudo VH; Killoran JH; Kim CK; Hornick JL; Nowak JA; Enzinger PC; Mamon HJ
    Ann Nucl Med; 2018 Apr; 32(3):165-174. PubMed ID: 29332233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of tumor response after neoadjuvant chemoradiotherapy in rectal cancer using (18)fluorine-2-deoxy-D-glucose positron emission tomography-computed tomography and serum carcinoembryonic antigen: a prospective study.
    Li QW; Zheng RL; Ling YH; Wang QX; Xiao WW; Zeng ZF; Fan W; Li LR; Gao YH
    Abdom Radiol (NY); 2016 Aug; 41(8):1448-55. PubMed ID: 27116012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma.
    Moore JL; Subesinghe M; Santaolalla A; Green M; Deere H; Van Hemelrijck M; Lagergren J; Chicklore S; Maisey N; Gossage JA; Kelly M; Baker CR; Davies AR;
    Eur Radiol; 2023 May; 33(5):3647-3659. PubMed ID: 36920518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase II clinical trial-PaCa-DD-041 (Eudra-CT 2009-011968-11).
    Zimmermann C; Distler M; Jentsch C; Blum S; Folprecht G; Zöphel K; Polster H; Troost EGC; Abolmaali N; Weitz J; Baumann M; Saeger HD; Grützmann R
    Strahlenther Onkol; 2021 Jan; 197(1):19-26. PubMed ID: 32638040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential Predictive Immune and Metabolic Biomarkers of Tumor Microenvironment Regarding Pathological and Clinical Response in Esophageal Cancer After Neoadjuvant Chemoradiotherapy: A Systematic Review.
    Wang HH; Steffens EN; Kats-Ugurlu G; van Etten B; Burgerhof JGM; Hospers GAP; Plukker JTM
    Ann Surg Oncol; 2024 Jan; 31(1):433-451. PubMed ID: 37777688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ineffectiveness of ¹⁸F-fluorodeoxyglucose positron emission tomography in the evaluation of tumor response after completion of neoadjuvant chemoradiation in esophageal cancer.
    Piessen G; Petyt G; Duhamel A; Mirabel X; Huglo D; Mariette C
    Ann Surg; 2013 Jul; 258(1):66-76. PubMed ID: 23470576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intra-tumor metabolic heterogeneity of gastric cancer on
    Liu G; Yin H; Cheng X; Wang Y; Hu Y; Liu T; Shi H
    Clin Exp Med; 2021 Feb; 21(1):129-138. PubMed ID: 32880779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of combined multiparametric MRI and FDG-PET/CT to identify well-responding rectal cancer patients before the start of neoadjuvant chemoradiation.
    Schurink NW; Min LA; Berbee M; van Elmpt W; van Griethuysen JJM; Bakers FCH; Roberti S; van Kranen SR; Lahaye MJ; Maas M; Beets GL; Beets-Tan RGH; Lambregts DMJ
    Eur Radiol; 2020 May; 30(5):2945-2954. PubMed ID: 32034488
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Linder G; Korsavidou-Hult N; Bjerner T; Ahlström H; Hedberg J
    Clin Radiol; 2019 Sep; 74(9):718-725. PubMed ID: 31221468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study.
    Borggreve AS; Mook S; Verheij M; Mul VEM; Bergman JJ; Bartels-Rutten A; Ter Beek LC; Beets-Tan RGH; Bennink RJ; van Berge Henegouwen MI; Brosens LAA; Defize IL; van Dieren JM; Dijkstra H; van Hillegersberg R; Hulshof MC; van Laarhoven HWM; Lam MGEH; van Lier ALHMW; Muijs CT; Nagengast WB; Nederveen AJ; Noordzij W; Plukker JTM; van Rossum PSN; Ruurda JP; van Sandick JW; Weusten BLAM; Voncken FEM; Yakar D; Meijer GJ;
    BMC Cancer; 2018 Oct; 18(1):1006. PubMed ID: 30342494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.